Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P06889 (Mol)
 630,302 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An enzyme which catalyzes the direct 2-electron reduction of prostaglandin H2 to prostaglandin F2 alpha has been purified from the microsomes of sheep seminal vesicles. This enzyme, called prostaglandin endoperoxide reductase, was found to be a monomer of 16,500 molecular mass. The activity of the enzyme was dependent on reduced glutathione, enhanced by heat-treatment, and inhibited by sulfhydryl reagents. The enzyme is not a glutathione S-transferase nor does it utilize prostaglandin D2 as a substrate, and thus is distinct from previously characterized prostaglandin F2 alpha biosynthetic enzymes. The protein also catalyzes the reduction of cumene hydroperoxide, but not hydrogen peroxide. Thus, this microsomal prostaglandin endoperoxide reductase may play an important role in the synthesis of prostaglandin F2 alpha in some tissues.
Biochem Mol Biol Int 1997 Feb
PMID:Isolation and characterization of an enzyme from sheep seminal vesicles that catalyzes the glutathione-dependent reduction of prostaglandin H2 to prostaglandin F2 alpha. 906 61

The expression of hsp70.2, an hsp70 gene family member, originally characterized by its high levels of expression in germ cells in the adult mouse testis, was detected in several other reproductive tissues, including epididymis, prostate, and seminal vesicles, as well as in extraembryonic tissues of mid-gestation fetuses. In addition, hybridization with RNA probes transcribed in the sense orientation surprisingly indicated the presence of slightly larger "antisense" transcripts in several tissues. The levels of antisense transcripts varied among the tissues, with the highest signal detected in the prostate and no signal being detectable in the testis. Consistent with these results, in situ hybridization analysis clearly localized the sense-orientation transcripts to pachytene spermatocytes, while no antisense-orientation transcripts were observed in adjacent sections of the same tubules. Our findings have thus shown that although hsp70.2 was expressed abundantly and in a highly stage-specific manner in the male germ line, it was also expressed in other murine tissues. Furthermore, we have made the surprising observation of antisense transcription of the hsp70.2 gene in several mouse tissues, revealing another level of complexity in the regulation and function of heat shock proteins.
Mol Reprod Dev 1996 Jan
PMID:Distinct transcripts are recognized by sense and antisense riboprobes for a member of the murine HSP70 gene family, HSP70.2, in various reproductive tissues. 911 Sep 44

The regional pattern of CD52 expression in the rat epididymis was followed by Northern analyses and carbohydrate-labelling of glycoconjugates on Western blots. CD52 mRNA showed a novel aspect of regionalization, namely region-dependent length differences in its poly(A) tail. 'Short' CD52 mRNA molecules were present in all parts of this organ and also in the seminal vesicles. Additionally, the cauda epididymidis contained mRNA molecules with an extended poly(A) tail. Their appearance coincided with the occurrence of the principal M(r) approximately 26 kDa glycopeptide in the cauda region, representing the CD52 product. CD52 expression seemed to be regulated or modulated synergistically by androgens, temperature, and (an) unknown testicular factor(s), depending on the poly(A) tail length of its mRNA. Androgens alone exerted an effect only on molecules with 'short' poly(A) tails. They were down-regulated in castrated animals, and restored to normal levels upon testosterone supplementation. However, 'long' CD52 mRNA molecules were not affected. Only if combined with the exposure of the epididymis to the elevated temperature of the abdomen, castration of animals resulted in a complete loss of the CD52 mRNA, including the 'long' cauda species. Loss of 'long' CD52 mRNA molecules was also observed when the abdominal location was combined with efferent duct ligation. This combination of treatments, however, did not affect 'short' CD52 mRNA levels. Loss of the 'long' CD52 mRNA molecules by any treatment coincided with a loss of the principal M(r) approximately 26 kDa glycopeptide from caudal protein extracts.
Mol Reprod Dev 1997 Dec
PMID:Regionalized expression of CD52 in rat epididymis is related to mRNA poly(A) tail length. 936 37

Kelce and Wilson (J. Mol. Med. 75, 198-207, 1997) have suggested that dosing chemicals to newly weaned male rats for 1 month may yield a useful assay for antiandrogens. This suggestion was supported by reference to unpublished data on the antiandrogen vinclozolin which indicated reductions in the weight of accessory sex organs. The necessity for dosing during the full approximately 30 days of the protocol was not justified. An evaluation of this protocol has commenced by the dosing of vinclozolin, cyproterone acetate, and anastrozole daily to newly weaned male rats for 3, 7, or 14 days. No changes were observed in accessory sex organs when vinclozolin or anastrozole was dosed for 3 days. Significant changes were observed in the absolute and relative weight of all of the sex accessory organs for rats dosed for 7 or 14 days with cyproterone acetate. The effects produced by vinclozolin and anastrozole when dosed for 7 or 14 days varied according to the duration of exposure with the main effects on the accessory sex organs being seen after 14 days of dosing. The effects produced after 7 days of dosing with vinclozolin or anastrozole in arachis oil had resolved 10 days after the last of the seven doses. Data are presented using either hydroxy propyl methyoxycellulose (HPMC) or arachis oil as vehicle, the former being recommended for general use. These preliminary results are encouraging, and the evaluation of the second 2 weeks of the suggested 30-day protocol is proceeding. Concurrent control data indicate that the relative weight of the liver, testes, and epididymides increases over the first 14 days post-weaning, while those of the kidney, the seminal vesicles, and prostate decrease. These changes in relative tissue weight were much less than the increase in relative weight of the uterus observed in female animals at puberty. That indicates that successful use of a final version of this assay will depend on access to inhouse control tissue weight data and the use of appropriate animal group sizes. These preliminary data are presented to reduce duplication of effort in this rapidly expanding area of toxicology.
 ...
PMID:The weanling male rat as an assay for endocrine disruption: preliminary observations. 944 23

As a clue to understand the role of androgen in rat seminal vesicle, we have isolated several cDNA clones of androgen-responsive mRNAs. During further characterizations of these cDNAs were in progress, a distinct cDNA clone designated p116 was isolated. The sequence study suggested the expression of a transcript predicting an alternative form of Sulfated Glycoprotein-2 (SGP-2)/clusterin. RT-PCR demonstrated the androgen-dependent expression of p116 transcript in the seminal vesicles. The transcript was also detectable in the ventral prostate, the liver and the thymus. Since SGP-2 has been suggested as a classical molecular marker of apoptosis, p116 transcript newly identified in the present study might provide a useful probe to further understand the roles of SGP-2 and its related proteins during the course of apoptotic process not only in male accessory sex organs, but also in many types of cells undergoing apoptosis.
Biochem Mol Biol Int 1998 Jan
PMID:Identification of a transcript predicting an alternative form of sulfated glycoprotein-2 (clusterin) in rat tissues. 950 43

The pharmacological profile of RU 58642, a new non-steroidal antiandrogen was investigated both in vitro and in vivo. In vitro, the compound displays a strong and specific affinity for androgen receptor. In vivo, its antiandrogenic activity was evaluated in castrated rat supplemented with testosterone propionate and in intact animals on prostate, seminal vesicles weight and serum levels of testosterone by oral and subcutaneous route. In castrated rats RU 58642 induced a significant decrease in prostate weight at a dose as low as 0.3 mg/kg whatever the route of administration. In intact rats its activity was compared to that of other non-steroidal antiandrogens such as flutamide, nilutamide and bicalutamide. RU 58642 proved to be significantly more potent than the reference compounds in reducing prostate weight: 3-30 times orally and 3-100 times subcutaneously, and thus the most potent antiandrogen to date to our knowledge. These results suggest that this compound may be very useful in the treatment of systemic androgen-dependent diseases.
J Steroid Biochem Mol Biol 1998 Jan
PMID:Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders. 956 15

Human seminal plasma sperm motility inhibitor (SPMI) proteins which are exclusively secreted from seminal vesicles, inhibit sperm motility. It is secreted as biologically active 52 kDa and a mixture of 71 and 76 kDa precursor forms, which are identical to semenogelin-I and II (Sg-I and Sg-II), respectively. To understand the molecular mechanism underlying the inhibition of sperm motility by SPMI proteins, we expressed human Sg-I and Sg-II genes in insect cells using a baculovirus system. The baculoviruses expressing full-size Sg-I and Sg-II proteins that were N-terminally-tagged with a hexahistidine were selected, and were infected with Sf 21 cells. The Sg-I and Sg-II proteins were purified from infected cells by column chromatography using Ni-NTA resin 48 h after infection. The full-size Sg-I and Sg-II proteins were obtained in soluble forms. However, they tended to aggregate to form a gel, as expected from naturally occurring semenogelin. Both the purified recombinant Sg-I and Sg-II proteins showed strong SPMI activities with a complete inhibition of sperm motility at 60 units/mg, equivalent to the natural proteins. This production system that permits the generation of purified Sg-I and Sg-II proteins, as well as mutant derivatives, will be helpful for further study on male infertility.
Int J Mol Med 1998 Dec
PMID:Characterization of recombinant precursor proteins of the human seminal plasma sperm motility inhibitor synthesized in insect cells. 985 Jul 38

Androgens affect many different target organs within the male reproductive tract to stimulate their development and secretory cytodifferentiation, and to maintain structure and function in adulthood. Castration causes regression of these organs via apoptosis. However, not all organs of the reproductive tract are equally sensitive to androgen withdrawal. The effects of castration on the mouse seminal vesicles (SVs) and bulbourethral glands (BUGs) were compared in terms of protein and DNA contents, epithelial apoptosis, and proliferative response of epithelial cells to androgen. Castration induced similar, marked decreases in protein contents in the SV and BUG by 2 days after castration which reached a minimum at 16 days post castration. Both organs underwent a decrease in DNA content, but the kinetics of this decline differed. In the SV, DNA content was significantly decreased by 4 days whereas in the BUG this did not occur until 16 days post castration. By day 16 both organs had regressed to roughly the same degree. The apoptotic index in the epithelium reflected this difference in timing as well. Apoptotic index of the SV epithelium was highest on day 3 after castration and declined thereafter. On the other hand, the apoptotic index in the BUG didn't begin to increase until 7 days after castration and became maximal on day 12. Daily injections of testosterone propionate (TP) from day 8, 16, or 30 after castration all increased epithelial labelling index in the SVs to a similar degree. However, the TP-induced increase in the epithelial labelling index in the BUG beginning on day 8 after castration was considerably less than that in BUGs receiving TP treatment from day 16 or 30 after castration. Thus, the proliferative response of the epithelium depended upon prior apoptosis in the gland, with the timing being delayed in the BUG as compared with the SV. The present results indicate that castration induces epithelial apoptosis and reduction in glandular DNA content considerably later in the BUG than in the SV though reduction in protein content in the BUG fell simultaneously with that in the SV.
J Steroid Biochem Mol Biol 1998 Oct
PMID:Later onset of apoptosis in the bulbourethral glands after castration compared to that in the seminal vesicles. 987 11

The role of FSH in gonadal tumorigenesis and, in particular, in human ovarian cancer has been debated. It is also unclear what role the elevated FSH levels in the inhibin-deficient mouse play in the gonadal tumorigenesis. To directly assess the role of FSH in gonadal growth, differentiation, and gonadal tumorigenesis, we have generated both gain-of-function and loss-of-function transgenic mutant mice. In the gain-of-function model, we have generated transgenic mice that ectopically overexpress human FSH from multiple tissues using a mouse metallothionein-1 promoter, achieving levels far exceeding those seen in postmenopausal women. Male transgenic mice are infertile despite normal testicular development and demonstrate enlarged seminal vesicles secondary to elevated serum testosterone levels. Female transgenic mice develop highly hemorrhagic and cystic ovaries, have elevated serum estradiol and progesterone levels, and are infertile, mimicking the features of human ovarian hyperstimulation and polycystic ovarian syndromes. Furthermore, the female transgenic mice develop enlarged and cystic kidneys and die between 6-13 weeks as a result of urinary bladder obstruction. In a complementary loss-of-function approach, we have generated double-homozygous mutant mice that lack both inhibin and FSH by a genetic intercross. In contrast to male mice lacking inhibin alone, 95% of which die of a cancer cachexia-like syndrome by 12 weeks of age, only 30% of the double-mutant male mice lacking both FSH and inhibin die by 1 yr of age. The remaining double-mutant male mice develop slow-growing and less hemorrhagic testicular tumors, which are noted after 12 weeks of age, and have minimal cachexia. Similarly, the double-mutant female mice develop slow-growing, less hemorrhagic ovarian tumors, and 70% of these mice live beyond 17 weeks. The double-mutant mice demonstrate minimal cachexia in contrast to female mice lacking only inhibin, which develop highly hemorrhagic ovarian tumors, leading to cachexia and death by 17 weeks of age in 95% of the cases. The milder cachexia-like symptoms of the inhibin and FSH double-mutant mice are correlated with low levels of serum estradiol and activin A and reduced levels of aromatase mRNA in the gonadal tumors. Based on these and our previous genetic analyses, we conclude that elevated FSH levels do not directly cause gonadal tumors. However, these results suggest FSH is an important trophic modifier factor for gonadal tumorigenesis in inhibin-deficient mice.
Mol Endocrinol 1999 Jun
PMID:Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. 1037 85

Human seminal plasma spontaneously coagulates after ejaculation. The major component of this coagulum is semenogelin 1, a 52-kDa protein expressed exclusively in the seminal vesicles. Recently, a sperm motility inhibitor has been found to be identical to semenogelin I, suggesting that it may also be a physiological sperm motility inhibitor. The protein is rapidly cleaved after ejaculation by the chymotrypsin-like prostatic protease prostate-specific antigen, resulting in liquefaction of the semen coagulum and the progressive release of motile spermatozoa. Some of the cleavage products of Sg I may also have various biological functions. While the semenogelin I protein is unique to human and higher primates, it has recently been shown to belong to a gene family having a similar gene structure but encoding widely differing proteins. The recently elucidated characteristics of the semenogelin I gene as well as the biochemical and functional properties of the encoded protein are reviewed, and an attempt is made to integrate the various findings into a model for semen coagulation, sperm immobilization and potential other functions.
Cell Mol Life Sci 1999 Jun
PMID:Semenogelin I: a coagulum forming, multifunctional seminal vesicle protein. 1041 73


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>